Grimes & Company’s Moderna MRNA Stock Holding History

Grimes & Company’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-572	Closed	-$220K	–	310
2021 Q3	$220K	Buy	+572	New	+$211K	0.01%	273

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Grimes & Company's MRNA Position: Q4 2021 in Review

Grimes & Company sold out of Moderna (MRNA) in Q4 2021, closing a stake of 572 shares — an estimated $220K sold.

Grimes & Company first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $220K in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Grimes & Company reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Grimes & Company sold 572 Moderna shares in Q4 2021, an estimated $220K.
Grimes & Company first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
Grimes & Company's Moderna position peaked at $220K in Q3 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Grimes & Company's 13F filing for Q4 2021, filed 1 Feb 2022.